(MENAFN- PR Newswire) MUMBAI, India and WARREN, N.J., May 22, 2024 /PRNewswire/ -- Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and its wholly owned subsidiary ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

Cipla Limited on Wednesday announced that it has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from the ...

IPSEN : The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen's Prior Approval Supplement application Ipsen (Euronext: IPN; ADR: IPSEY) announced today ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a prior approval supplement application for the extended dosing interval of lanreotide ...

Mumbai (Maharashtra) [India], May 22 (ANI): Mumbai-headquartered pharma major, Cipla's US arm has secured final approval from the United States Food and Drug Administration (USFDA) for its Lanreotide ...

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline ® Autogel ® (lanreotide injection) 60, 90, and 120 ...

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...

Ipsen (Euronext : IPN ; ADR : IPSEY) today announced its decision to set up its own oncology team to commercialize Somatuline ® Depot ® (lanreotide) 120 mg Injection (referred to as Somatuline ®) in ...

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...